共 50 条
Implementation of pharmacogenetics in a clozapine treatment resistant patient: a case report
被引:4
|作者:
Sanguesa, Estela
[1
]
Cirujeda, Christine
[2
]
Concha, Julia
[1
]
Pablo Padilla, Pedro
[2
]
Pilar Ribate, Maria
[1
]
Belen Garcia, Cristina
[1
]
机构:
[1] Univ San Jorge, Fac Hlth Sci, Villanueva De Gallego, Zaragoza, Spain
[2] Hermanas Hosp, Ctr Neuropsiquiatr Nuestra Senora Carmen, Zaragoza, Spain
关键词:
genotype;
pharmacodynamics;
pharmacokinetics;
therapeutic drug monitoring;
treatment-resistant schizophrenia;
AUGMENTATION STRATEGIES;
PLASMA CLOZAPINE;
SCHIZOPHRENIA;
POLYMORPHISM;
ANTIPSYCHOTICS;
GUIDELINES;
VARIANTS;
5-HTTLPR;
SMOKING;
SAFETY;
D O I:
10.2217/pgs-2019-0074
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
We report the case of a young Caucasian male with disorganized chronic schizophrenia, an active smoker and nonresponder to 400 mg of clozapine/day. Therapeutic clozapine monitoring was analyzed revealing a low clozapine:norclozapine ratio. An additional pharmacogenetic test was carried out showing that the patient carried *1F variant (CYP1A2 gene), which has been associated with nonresponse to clozapine in smoker patients. A genetic variation in the SLC6A4 gene was also found, which could be related to the poor response to clozapine. The remainder of the genes analyzed (CYP2D6, ABCB1 and HTR2A) were not directly associated with the patient's phenotype. The dose of clozapine was increased to 600 mg/day, reaching the therapeutic range. This case shows how pharmacogenetics can help in understanding the value of plasma levels to provide clinical improvement.
引用
下载
收藏
页码:871 / 877
页数:7
相关论文